Prexa Pharmaceuticals, a US-based developer of therapies for the human central nervous system, has raised $7m in its series B round from a consortium including drug maker Shire Pharmaceuticals.
Alongside Shire, which focuses on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases, in the consortium was venture capital firm Advent Healthcare Ventures, which led the round. Advent founded Prexa in 2006, and invested $3.1m in it’s A round.
Charles Cohen, partner at Advent and executive chairman of Prexa, said: "We are excited about Shire’s participation in this round of financing, and are pleased that they share our confidence in Prexa’s unique approach to treating CNS diseases and disorders."